Experts discuss the central role of patient education and the strategic use of topical therapies in managing atopic dermatitis (AD), emphasizing the need for clear communication, age-appropriate ...

Experts discuss the recent FDA approval of topical JAK inhibitors for children 2 years or older as a promising advancement in pediatric atopic dermatitis treatment, highlighting their efficacy, their ...

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...

Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...

Children with moderate to severe atopic dermatitis had improved skin barrier function with 16-week dupilumab treatment in both lesional and nonlesional skin, according to data published in Annals of ...

Exposure to dupilumab is associated with an increased risk of being diagnosed with cutaneous autoimmune diseases in children ...

Credit: Getty Images. The INTEGUMENT-PED trial included 652 children 2 to 5 years of age with mild to moderate atopic dermatitis who had a mean BSA of 22% and a range from 3% to 82%. A phase 3 trial ...

A review in the Archives of Dermatological Research focuses on the similarities and differences between psoriasis and atopic dermatitis (AD) in pediatric patients. The authors note that distinguishing ...

For children with atopic dermatitis (AD), dupilumab treatment restores skin barrier function, according to a study published ...

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe disease reported more itch and pain than those with mild disease. Those with ...